[S01GX11, alcaftadine, The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Haloperidol.]
[S02DA03, antipyrine, The serum concentration of Haloperidol can be increased when it is combined with Antipyrine.]
[G03XB02, ulipristal, The serum concentration of Haloperidol can be increased when it is combined with Ulipristal.]
[J01GA01, streptomycin, Haloperidol may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Succinylcholine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01CG01, sulbactam, Haloperidol may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The serum concentration of Haloperidol can be increased when it is combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Haloperidol can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Haloperidol.]
[J01EC03, sulfamoxole, The metabolism of Haloperidol can be decreased when combined with Sulfamoxole.]
[J01EB06, sulfanilamide, The serum concentration of Haloperidol can be increased when it is combined with Sulfanilamide.]
[J01EB04, sulfapyridine, The metabolism of Haloperidol can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Haloperidol.]
[M01AB02, sulindac, The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulindac.]
[N05AL01, sulpiride, Haloperidol may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Haloperidol.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Haloperidol.]
[M01AX04, apazone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Azapropazone.]
[N06DA01, tacrine, The metabolism of Haloperidol can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Haloperidol.]
[N05CD07, temazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Temazepam.]
[L01CB02, teniposide, The serum concentration of Haloperidol can be increased when it is combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Haloperidol.]
[B01AE07, dabigatran etexilate, Haloperidol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The serum concentration of Haloperidol can be increased when it is combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Haloperidol.]
[S01HA03, tetracaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tetracaine.]
[S03AA02, tetracycline, The serum concentration of Haloperidol can be increased when it is combined with Tetracycline.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AE05, lurasidone, The metabolism of Lurasidone can be decreased when combined with Haloperidol.]
[A04AD10, dronabinol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Haloperidol.]
[L04AX02, thalidomide, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The serum concentration of Haloperidol can be increased when it is combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Haloperidol can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Haloperidol.]
[R06AD03, thiethylperazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Thiethylperazine.]
[L01AC01, thiotepa, The serum concentration of Haloperidol can be increased when it is combined with Thiotepa.]
[N05CA19, thiopental, The risk or severity of CNS depression can be increased when Haloperidol is combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thioridazine is combined with Haloperidol.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Haloperidol.]
[C01BB04, aprindine, The serum concentration of Aprindine can be increased when it is combined with Haloperidol.]
[G04BE06, moxisylyte, Haloperidol may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tiapride.]
[B01AC05, ticlopidine, The serum concentration of Ticlopidine can be increased when it is combined with Haloperidol.]
[N02AX01, tilidine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Haloperidol.]
[P01AB02, tinidazole, The serum concentration of Haloperidol can be increased when it is combined with Tinidazole.]
[S01AA12, tobramycin, Haloperidol may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Haloperidol.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Haloperidol.]
[M02AA21, tolmetin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Haloperidol.]
[N06AF04, tranylcypromine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Haloperidol.]
[L01XF01, tretinoin, The serum concentration of Haloperidol can be increased when it is combined with Tretinoin.]
[S01BA05, triamcinolone, The serum concentration of Haloperidol can be increased when it is combined with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Triazolam.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Haloperidol may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Triflupromazine.]
[S01BA09, clobetasone, The serum concentration of Haloperidol can be increased when it is combined with Clobetasone.]
[S01BA10, alclometasone, The serum concentration of Haloperidol can be increased when it is combined with Alclometasone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Haloperidol.]
[R03BA07, mometasone, The serum concentration of Haloperidol can be increased when it is combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Haloperidol.]
[S01ED04, metipranolol, The serum concentration of Metipranolol can be increased when it is combined with Haloperidol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Haloperidol.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Haloperidol.]
[J01EA01, trimethoprim, The serum concentration of Haloperidol can be increased when it is combined with Trimethoprim.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Haloperidol.]
[R06AC04, tripelennamine, The serum concentration of Haloperidol can be increased when it is combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Haloperidol.]
[A03BB01, butylscopolamine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The serum concentration of Haloperidol can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tryptophan.]
[M03AA02, tubocurarine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Haloperidol can be increased when it is combined with Roflumilast.]
[L01FX04, ipilimumab, Haloperidol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Vandetanib is combined with Haloperidol.]
[R02AA14, oxyquinoline, Haloperidol may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The serum concentration of Haloperidol can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The serum concentration of Haloperidol can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Haloperidol can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Haloperidol can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Haloperidol.]
[S01AA28, vancomycin, Haloperidol may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Haloperidol.]
[B01AF01, rivaroxaban, The serum concentration of Haloperidol can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Haloperidol.]
[B01AC24, ticagrelor, The serum concentration of Haloperidol can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, The serum concentration of Haloperidol can be increased when it is combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Haloperidol can be increased when it is combined with Vinblastine.]
[L01CA02, vincristine, The serum concentration of Haloperidol can be increased when it is combined with Vincristine.]
[L01CA03, vindesine, The serum concentration of Haloperidol can be increased when it is combined with Vindesine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[A11HA03, vitamin E, The serum concentration of Haloperidol can be increased when it is combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Haloperidol can be increased when it is combined with Warfarin.]
[S01AA13, fusidic acid, The serum concentration of Haloperidol can be increased when it is combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The serum concentration of Haloperidol can be increased when it is combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Haloperidol.]
[J05AE02, indinavir, The serum concentration of Haloperidol can be increased when it is combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Levetiracetam.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L01FX05, brentuximab vedotin, The serum concentration of Haloperidol can be increased when it is combined with Brentuximab vedotin.]
[M05BA05, tiludronic acid, Haloperidol may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Haloperidol may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Haloperidol.]
[R03DC01, zafirlukast, The serum concentration of Haloperidol can be increased when it is combined with Zafirlukast.]
[A02BC04, rabeprazole, The serum concentration of Haloperidol can be increased when it is combined with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Haloperidol.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Ziprasidone.]
[G03AC10, drospirenone, The serum concentration of Haloperidol can be increased when it is combined with Drospirenone.]
[V03AC02, deferiprone, Haloperidol may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The serum concentration of Haloperidol can be increased when it is combined with Ruxolitinib.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Haloperidol.]
[J01DH04, doripenem, Haloperidol may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Haloperidol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Haloperidol can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Haloperidol.]
[M03AC04, atracurium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Haloperidol.]
[M01CB03, auranofin, Haloperidol may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01XJ01, vismodegib, The serum concentration of Haloperidol can be increased when it is combined with Vismodegib.]
[L01EK01, axitinib, The serum concentration of Haloperidol can be increased when it is combined with Axitinib.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Haloperidol.]
[H02AB11, prednylidene, The serum concentration of Haloperidol can be increased when it is combined with Prednylidene.]
[B03XA04, peginesatide, Haloperidol may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Haloperidol may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Haloperidol.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Haloperidol.]
[M03BX01, baclofen, The risk or severity of CNS depression can be increased when Haloperidol is combined with Baclofen.]
[A08AA11, lorcaserin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Haloperidol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Haloperidol can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Haloperidol can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Haloperidol can be increased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Haloperidol can be increased when it is combined with Bosutinib.]
[L04AA31, teriflunomide, The serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide.]
[H02AA01, aldosterone, The serum concentration of Haloperidol can be increased when it is combined with Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Haloperidol can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Barbital.]
[D02BA02, octinoxate, Haloperidol may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Haloperidol.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Haloperidol.]
[S01GA07, brimonidine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Brimonidine.]
[N04BD02, rasagiline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Rasagiline.]
[C08CA13, lercanidipine, The serum concentration of Haloperidol can be increased when it is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of CNS depression can be increased when Haloperidol is combined with Donepezil.]
[N03AX22, perampanel, The risk or severity of CNS depression can be increased when Haloperidol is combined with Perampanel.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Haloperidol.]
[N02CC03, zolmitriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The serum concentration of Haloperidol can be increased when it is combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Haloperidol may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of CNS depression can be increased when Haloperidol is combined with Diethyl ether.]
[L01EX07, cabozantinib, The serum concentration of Haloperidol can be increased when it is combined with Cabozantinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Haloperidol.]
[G04BE03, sildenafil, The serum concentration of Haloperidol can be increased when it is combined with Sildenafil.]
[V08CA11, gadofosveset, Haloperidol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The serum concentration of Haloperidol can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Haloperidol can be increased when it is combined with Apixaban.]
[A16AX08, teduglutide, Haloperidol may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C10AX12, lomitapide, The serum concentration of Haloperidol can be increased when it is combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Haloperidol.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Haloperidol.]
[A10BH04, alogliptin, The serum concentration of Haloperidol can be increased when it is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The serum concentration of Haloperidol can be increased when it is combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pomalidomide.]
[G03XC05, ospemifene, The serum concentration of Haloperidol can be increased when it is combined with Ospemifene.]
[N02BA10, benorilate, The therapeutic efficacy of Haloperidol can be increased when used in combination with Benorilate.]
[N05AD07, benperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Benperidol.]
[A10BK02, canagliflozin, The serum concentration of Haloperidol can be increased when it is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Haloperidol.]
[M04AB03, benzbromarone, The metabolism of Haloperidol can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Haloperidol.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Haloperidol.]
[R02AD01, benzocaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Haloperidol.]
[L03AA12, ancestim, Haloperidol may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The serum concentration of Haloperidol can be increased when it is combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Haloperidol.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Haloperidol is combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Haloperidol.]
[R02AX03, benzydamine, The therapeutic efficacy of Haloperidol can be increased when used in combination with Benzydamine.]
[L01EE01, trametinib, Haloperidol may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Haloperidol may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of CNS depression can be increased when Haloperidol is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Bepridil is combined with Haloperidol.]
[C02KX05, riociguat, The serum concentration of Haloperidol can be increased when it is combined with Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Haloperidol.]
[C02KX04, macitentan, The serum concentration of Haloperidol can be increased when it is combined with Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Haloperidol.]
[N06AX26, vortioxetine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vortioxetine.]
[G03AC08, etonogestrel, The serum concentration of Haloperidol can be increased when it is combined with Etonogestrel.]
[N03AF04, eslicarbazepine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Haloperidol can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, The serum concentration of Haloperidol can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, Haloperidol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The serum concentration of Haloperidol can be increased when it is combined with Dapagliflozin.]
[C01CA27, droxidopa, Haloperidol may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Haloperidol.]
[N05CH03, tasimelteon, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Haloperidol can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The serum concentration of Haloperidol can be increased when it is combined with Apremilast.]
[L02BG02, formestane, Haloperidol may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The serum concentration of Haloperidol can be increased when it is combined with Betamethasone.]
[S01ED02, betaxolol, The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Haloperidol.]
[V03AB34, fomepizole, Haloperidol may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The serum concentration of Haloperidol can be increased when it is combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Haloperidol.]
[L04AC11, siltuximab, The serum concentration of Haloperidol can be increased when it is combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Haloperidol.]
[B01AC26, vorapaxar, The serum concentration of Haloperidol can be increased when it is combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Haloperidol.]
[B01AA07, acenocoumarol, The serum concentration of Haloperidol can be increased when it is combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Haloperidol can be increased when combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Haloperidol can be increased when it is combined with Idelalisib.]
[N01AX05, alfaxalone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Alfaxalone.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Haloperidol.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Haloperidol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[D11AA01, glycopyrronium, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05CM19, suvorexant, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Haloperidol.]
[J01XA05, oritavancin, The serum concentration of Haloperidol can be increased when it is combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Acepromazine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Haloperidol.]
[A06AH03, naloxegol, The metabolism of Naloxegol can be decreased when combined with Haloperidol.]
[N04AA02, biperiden, The serum concentration of Haloperidol can be increased when it is combined with Biperiden.]
[A11HA08, tocophersolan, The serum concentration of Haloperidol can be increased when it is combined with Tocofersolan.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be increased when it is combined with Haloperidol.]
[L01EX09, nintedanib, The serum concentration of Haloperidol can be increased when it is combined with Nintedanib.]
[S03AA06, gentamicin, Haloperidol may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The serum concentration of Haloperidol can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Haloperidol.]
[B01AA01, dicumarol, The metabolism of Haloperidol can be decreased when combined with Dicoumarol.]
[B01AF03, edoxaban, Haloperidol may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Haloperidol.]
[L04AC10, secukinumab, The metabolism of Haloperidol can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Haloperidol can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Haloperidol.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Haloperidol.]
[J05AP07, daclatasvir, The serum concentration of Haloperidol can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The serum concentration of Haloperidol can be increased when it is combined with Acetaminophen.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[A03AA09, difemerine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Haloperidol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J05AP06, asunaprevir, The serum concentration of Haloperidol can be increased when it is combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Haloperidol.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Haloperidol.]
[A04AD14, rolapitant, The serum concentration of Haloperidol can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Haloperidol.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Haloperidol.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Haloperidol.]
[M02AA25, aceclofenac, The therapeutic efficacy of Haloperidol can be increased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Acetazolamide.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Haloperidol.]
[N05AB07, acetophenazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Acetophenazine.]
[A02BC03, lansoprazole, The serum concentration of Haloperidol can be increased when it is combined with Lansoprazole.]
[V03AB37, idarucizumab, Haloperidol may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The serum concentration of Haloperidol can be increased when it is combined with Trabectedin.]
[J02AC05, isavuconazole, The serum concentration of Haloperidol can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Haloperidol can be increased when it is combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Haloperidol can be increased when it is combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Haloperidol.]
[L01XG03, ixazomib, The serum concentration of Haloperidol can be increased when it is combined with Ixazomib.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Haloperidol.]
[B01AC27, selexipag, The serum concentration of Haloperidol can be increased when it is combined with Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Haloperidol.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Haloperidol.]
[M04AB05, lesinurad, Haloperidol may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[J05AP10, elbasvir, The serum concentration of Haloperidol can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Haloperidol can be increased when it is combined with Grazoprevir.]
[N05CA05, aprobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Aprobarbital.]
[M01AE16, alminoprofen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Brivaracetam.]
[L01XX52, venetoclax, The serum concentration of Haloperidol can be increased when it is combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Haloperidol may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Alverine.]
[D07AC11, amcinonide, The serum concentration of Haloperidol can be increased when it is combined with Amcinonide.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol.]
[N06AA19, amineptin, The serum concentration of Amineptine can be increased when it is combined with Haloperidol.]
[C08CA01, amlodipine, The risk or severity of QTc prolongation can be increased when Amlodipine is combined with Haloperidol.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Haloperidol.]
[N06BX11, aniracetam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Haloperidol can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01ED03, levobunolol, The serum concentration of Levobunolol can be increased when it is combined with Haloperidol.]
[N01BB01, bupivacaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Haloperidol.]
[N07BC01, buprenorphine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Haloperidol.]
[N05BE01, buspirone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Buspirone.]
[L01AB01, busulfan, The serum concentration of Haloperidol can be increased when it is combined with Busulfan.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Haloperidol.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Haloperidol.]
[M02AA03, clofezone, The serum concentration of Haloperidol can be increased when it is combined with Rabeprazole.]
[N02AF01, butorphanol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Haloperidol.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Haloperidol.]
[S01GX07, azelastine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The serum concentration of Haloperidol can be increased when it is combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Haloperidol.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Haloperidol.]
[A07EC04, balsalazide, The therapeutic efficacy of Haloperidol can be increased when used in combination with Balsalazide.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Haloperidol.]
[A06AH05, naldemedine, Haloperidol may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Deutetrabenazine is combined with Haloperidol.]
[N02BF02, pregabalin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Haloperidol can be decreased when combined with Caffeine.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Haloperidol.]
[S01HA02, benoxinate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The serum concentration of Haloperidol can be increased when it is combined with Calcitriol.]
[P01CA02, benznidazole, Haloperidol may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.]
[J05AF06, abacavir, Haloperidol may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The serum concentration of Haloperidol can be increased when it is combined with Tipranavir.]
[N07XX13, valbenazine, The serum concentration of Haloperidol can be increased when it is combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Haloperidol can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The serum concentration of Haloperidol can be increased when it is combined with Midostaurin.]
[L01ED04, brigatinib, The serum concentration of Haloperidol can be increased when it is combined with Brigatinib.]
[N04BD03, safinamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Safinamide.]
[L04AC14, sarilumab, The serum concentration of Haloperidol can be increased when it is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Haloperidol.]
[D01AC10, bifonazole, The serum concentration of Haloperidol can be increased when it is combined with Bifonazole.]
[P03AC02, bioallethrin, The serum concentration of Haloperidol can be increased when it is combined with Bioallethrin.]
[L01BC06, capecitabine, The metabolism of Haloperidol can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Haloperidol can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Haloperidol can be increased when it is combined with Neratinib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Haloperidol.]
[L01EM02, copanlisib, The serum concentration of Haloperidol can be increased when it is combined with Copanlisib.]
[L01EF03, abemaciclib, The serum concentration of Haloperidol can be increased when it is combined with Abemaciclib.]
[A02BX12, bismuth subnitrate, Haloperidol may increase the neurotoxic activities of Bismuth subnitrate.]
[C07AB07, bisoprolol, The serum concentration of Haloperidol can be increased when it is combined with Bisoprolol.]
[S01EC04, brinzolamide, The serum concentration of Haloperidol can be increased when it is combined with Brinzolamide.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Haloperidol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Haloperidol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Haloperidol.]
[N05AD06, bromperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The serum concentration of Haloperidol can be increased when it is combined with Budesonide.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Haloperidol.]
[M01AB07, bumadizone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Bumadizone.]
[L01EL02, acalabrutinib, The serum concentration of Haloperidol can be increased when it is combined with Acalabrutinib.]
[N05CA03, butobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Butobarbital.]
[J05AX18, letermovir, The serum concentration of Haloperidol can be increased when it is combined with Letermovir.]
[N06AA15, butriptyline, The serum concentration of Butriptyline can be increased when it is combined with Haloperidol.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Haloperidol.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Haloperidol.]
[N01BX04, capsaicin, The serum concentration of Haloperidol can be increased when it is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Haloperidol.]
[N05CA08, butylvinal, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Haloperidol.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Macimorelin is combined with Haloperidol.]
[L02BB05, apalutamide, The serum concentration of Haloperidol can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Haloperidol can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Haloperidol.]
[L03AB06, interferon alfa-n1, The metabolism of Haloperidol can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Haloperidol can be increased when it is combined with Carvedilol.]
[B02BX09, fostamatinib, The serum concentration of Haloperidol can be increased when it is combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Haloperidol can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, The serum concentration of Haloperidol can be increased when it is combined with Baricitinib.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Haloperidol.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Haloperidol.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01GB14, plazomicin, Haloperidol may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Haloperidol.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Haloperidol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Haloperidol.]
[P01BA07, tafenoquine, The serum concentration of Tafenoquine can be increased when it is combined with Haloperidol.]
[A16AX14, migalastat, Haloperidol may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Stiripentol.]
[J05AG06, doravirine, The serum concentration of Haloperidol can be increased when it is combined with Doravirine.]
[J01AA13, eravacycline, The serum concentration of Haloperidol can be increased when it is combined with Eravacycline.]
[L01EM04, duvelisib, The serum concentration of Haloperidol can be increased when it is combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Haloperidol can be increased when it is combined with Dacomitinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Haloperidol.]
[N05CM04, carbromal, The risk or severity of CNS depression can be increased when Haloperidol is combined with Carbromal.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Haloperidol.]
[N01BA04, chloroprocaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Haloperidol may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The therapeutic efficacy of Haloperidol can be increased when used in combination with Lornoxicam.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Haloperidol.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Haloperidol.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Haloperidol.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Haloperidol.]
[L01ED05, lorlatinib, The serum concentration of Haloperidol can be increased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Haloperidol can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Haloperidol can be decreased when combined with Carmustine.]
[L01EX12, larotrectinib, The serum concentration of Haloperidol can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Haloperidol.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Glasdegib is combined with Haloperidol.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Haloperidol.]
[A06AX05, prucalopride, The serum concentration of Haloperidol can be increased when it is combined with Prucalopride.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Haloperidol.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Haloperidol.]
[A03FA08, cinitapride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cinitapride.]
[S01ED05, carteolol, The risk or severity of QTc prolongation can be increased when Carteolol is combined with Haloperidol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Haloperidol.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Haloperidol is combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Haloperidol is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Haloperidol.]
[N06BA14, solriamfetol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Brexanolone.]
[L01EN01, erdafitinib, The serum concentration of Haloperidol can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Haloperidol can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Haloperidol can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Haloperidol can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Haloperidol can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The serum concentration of Haloperidol can be increased when it is combined with Alpelisib.]
[L01FX14, polatuzumab vedotin, The serum concentration of Haloperidol can be increased when it is combined with Polatuzumab vedotin.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L01XX66, selinexor, The serum concentration of Haloperidol can be increased when it is combined with Selinexor.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Haloperidol can be increased when it is combined with Darolutamide.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Haloperidol.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Haloperidol.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Haloperidol.]
[L04AA44, upadacitinib, The serum concentration of Haloperidol can be increased when it is combined with Upadacitinib.]
[L01EJ02, fedratinib, The serum concentration of Haloperidol can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Haloperidol.]
[N07XX11, pitolisant, The serum concentration of Haloperidol can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Haloperidol.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Haloperidol.]
[N04CX01, istradefylline, The serum concentration of Haloperidol can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Haloperidol.]
[S01EX02, dapiprazole, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dapiprazole.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DB01, cephalexin, The serum concentration of Haloperidol can be increased when it is combined with Cephalexin.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Haloperidol.]
[G03DB05, demegestone, The serum concentration of Haloperidol can be increased when it is combined with Demegestone.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Haloperidol can be increased when it is combined with Trastuzumab emtansine.]
[N02CC08, lasmiditan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lasmiditan.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Haloperidol.]
[G03AC09, desogestrel, The serum concentration of Haloperidol can be increased when it is combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Haloperidol.]
[N03AX25, cenobamate, The serum concentration of Haloperidol can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Haloperidol can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Haloperidol may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Haloperidol.]
[L01FX13, enfortumab vedotin, The serum concentration of Haloperidol can be increased when it is combined with Enfortumab vedotin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Haloperidol.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Haloperidol.]
[S01XA12, dexpanthenol, Haloperidol may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dezocine.]
[L01EX18, avapritinib, The serum concentration of Haloperidol can be increased when it is combined with Avapritinib.]
[N05CM21, lemborexant, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lemborexant.]
[L01XX72, tazemetostat, The serum concentration of Haloperidol can be increased when it is combined with Tazemetostat.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Haloperidol.]
[M01AX21, diacetylrhein, The serum concentration of Haloperidol can be increased when it is combined with Diacerein.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be decreased when combined with Haloperidol.]
[J05AB16, remdesivir, The serum concentration of Haloperidol can be increased when it is combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Haloperidol.]
[H02CA02, osilodrostat, The serum concentration of Haloperidol can be increased when it is combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Haloperidol can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Frovatriptan.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Haloperidol.]
[N05CC04, dichloralphenazone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Haloperidol.]
[R02AA03, dichlorobenzyl alcohol, Haloperidol may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, The serum concentration of Haloperidol can be increased when it is combined with Dienogest.]
[A07DA04, difenoxin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Difenoxin.]
[D07AC19, difluprednate, The serum concentration of Haloperidol can be increased when it is combined with Difluprednate.]
[N02AA08, dihydrocodeine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Eletriptan.]
[M01AH02, rofecoxib, The serum concentration of Haloperidol can be increased when it is combined with Rofecoxib.]
[L01XF03, bexarotene, The serum concentration of Haloperidol can be increased when it is combined with Bexarotene.]
[C08CA16, clevidipine, The serum concentration of Haloperidol can be increased when it is combined with Clevidipine.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Haloperidol.]
[N03AG02, dipropylacetamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Valpromide.]
[J01FA13, dirithromycin, The serum concentration of Haloperidol can be increased when it is combined with Dirithromycin.]
[S03AA08, chloramphenicol, The serum concentration of Haloperidol can be increased when it is combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Haloperidol.]
[N05BA02, chlordiazepoxide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chlordiazepoxide.]
[L01EN02, pemigatinib, The serum concentration of Haloperidol can be increased when it is combined with Pemigatinib.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Haloperidol.]
[A03AA08, dihexyverine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The serum concentration of Haloperidol can be increased when it is combined with Capmatinib.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Haloperidol.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Haloperidol.]
[D07XB03, fluprednidene, The serum concentration of Haloperidol can be increased when it is combined with Fluprednidene.]
[G04BD09, trospium, The serum concentration of Haloperidol can be increased when it is combined with Trospium.]
[M01AC04, droxicam, The therapeutic efficacy of Haloperidol can be increased when used in combination with Droxicam.]
[L01EX19, ripretinib, The serum concentration of Haloperidol can be increased when it is combined with Ripretinib.]
[V08CA05, mangafodipir, Haloperidol may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of QTc prolongation can be increased when Selpercatinib is combined with Haloperidol.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of CNS depression can be increased when Haloperidol is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dyclonine.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Haloperidol.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Haloperidol.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Haloperidol.]
[J05AX29, fostemsavir, The serum concentration of Haloperidol can be increased when it is combined with Fostemsavir.]
[P01BB01, proguanil, The serum concentration of Haloperidol can be increased when it is combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Haloperidol is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Haloperidol can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Haloperidol is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Haloperidol.]
[L01EX23, pralsetinib, The serum concentration of Haloperidol can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[D01AE07, chlorphenesin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chlorphenesin.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Haloperidol.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Haloperidol.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Haloperidol.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Haloperidol.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The serum concentration of Haloperidol can be increased when it is combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Etifoxine.]
[N02BA07, ethenzamide, The therapeutic efficacy of Haloperidol can be increased when used in combination with Ethenzamide.]
[N02BA03, choline salicylate, Haloperidol may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The serum concentration of Haloperidol can be increased when it is combined with Etynodiol.]
[M01AB08, etodolac, The therapeutic efficacy of Haloperidol can be increased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Haloperidol can be increased when used in combination with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Haloperidol can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The serum concentration of Haloperidol can be increased when it is combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Haloperidol can be increased when it is combined with Relugolix.]
[M01AX25, chondroitin sulfates, Haloperidol may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, Haloperidol may increase the neurotoxic activities of Naxitamab.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Haloperidol.]
[P03AX07, abametapir, The serum concentration of Haloperidol can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Haloperidol can be increased when it is combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Haloperidol can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Haloperidol.]
[M01AE05, fenbufen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Fenbufen.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Haloperidol.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Haloperidol.]
[G04CB01, finasteride, The serum concentration of Haloperidol can be increased when it is combined with Finasteride.]
[J01DD15, cefdinir, Haloperidol may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Haloperidol.]
[R03BA03, flunisolide, The serum concentration of Haloperidol can be increased when it is combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The serum concentration of Haloperidol can be increased when it is combined with Fluocinolone acetonide.]
[N02BG07, flupirtine, Haloperidol may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Haloperidol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Haloperidol.]
[N01AB05, trichloroethylene, The risk or severity of CNS depression can be increased when Haloperidol is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Haloperidol can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The serum concentration of Haloperidol can be increased when it is combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Gabapentin.]
[V08CA04, gadoteridol, Haloperidol may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Haloperidol.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Haloperidol.]
[L01XX73, sotorasib, The serum concentration of Haloperidol can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Haloperidol.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Haloperidol.]
[L01XA01, cisplatin, Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Citalopram is combined with Haloperidol.]
[H01AC07, somapacitan, The metabolism of Haloperidol can be increased when combined with Somapacitan.]
[J02AX07, ibrexafungerp, The serum concentration of Haloperidol can be increased when it is combined with Ibrexafungerp.]
[C03DA05, finerenone, The serum concentration of Haloperidol can be increased when it is combined with Finerenone.]
[L04AA48, belumosudil, The serum concentration of Haloperidol can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The serum concentration of Haloperidol can be increased when it is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Haloperidol can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The serum concentration of Haloperidol can be increased when it is combined with Tisotumab vedotin.]
[N02CD07, atogepant, The serum concentration of Haloperidol can be increased when it is combined with Atogepant.]
[V09AB03, ioflupane I-123, Haloperidol may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Haloperidol may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Haloperidol may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[L04AA59, avacopan, The serum concentration of Haloperidol can be increased when it is combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Haloperidol.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Haloperidol.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Haloperidol.]
[J01FF01, clindamycin, The serum concentration of Haloperidol can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The risk or severity of CNS depression can be increased when Haloperidol is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Haloperidol can be increased when it is combined with Asciminib.]
[L02BG06, exemestane, The serum concentration of Haloperidol can be increased when it is combined with Exemestane.]
[J05AX10, maribavir, The serum concentration of Haloperidol can be increased when it is combined with Maribavir.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Haloperidol.]
[D07AD01, clobetasol, The serum concentration of Haloperidol can be increased when it is combined with Clobetasol.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Haloperidol.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Haloperidol.]
[C10AB01, clofibrate, The serum concentration of Haloperidol can be increased when it is combined with Clofibrate.]
[B06AX04, mitapivat, The serum concentration of Haloperidol can be increased when it is combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Haloperidol.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be increased when it is combined with Haloperidol.]
[N03AE01, clonazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Haloperidol.]
[C01EB24, mavacamten, The serum concentration of Haloperidol can be increased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Haloperidol.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC08, vonoprazan, The serum concentration of Haloperidol can be increased when it is combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Haloperidol.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Haloperidol.]
[L01XX77, adagrasib, The risk or severity of QTc prolongation can be increased when Adagrasib is combined with Haloperidol.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Haloperidol.]
[L01EN04, futibatinib, The serum concentration of Haloperidol can be increased when it is combined with Futibatinib.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Haloperidol.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Haloperidol.]
[J01GB12, arbekacin, Haloperidol may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Haloperidol can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Cocaine is combined with Haloperidol.]
[M09AX11, palovarotene, The serum concentration of Haloperidol can be increased when it is combined with Palovarotene.]
[C02KB01, metyrosine, Haloperidol may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Haloperidol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Proquazone.]
[R05DA04, codeine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Haloperidol.]
[A03AB10, hexocyclium, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Haloperidol may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L04AA13, leflunomide, The serum concentration of Haloperidol can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Haloperidol.]
[A04AA03, tropisetron, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ifenprodil.]
[A10BX03, nateglinide, The serum concentration of Haloperidol can be increased when it is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Haloperidol can be increased when used in combination with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Haloperidol.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Haloperidol.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Haloperidol.]
[R03BA08, ciclesonide, The serum concentration of Haloperidol can be increased when it is combined with Ciclesonide.]
[B01AC10, indobufen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Haloperidol.]
[J05AB14, valganciclovir, Haloperidol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Haloperidol may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Haloperidol may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Haloperidol may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Haloperidol may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Haloperidol may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The serum concentration of Haloperidol can be increased when it is combined with Valdecoxib.]
[N02CC05, almotriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Almotriptan.]
[M01AH04, parecoxib, The serum concentration of Haloperidol can be increased when it is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Haloperidol.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Haloperidol.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Haloperidol.]
[N05BA10, ketazolam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ketazolam.]
[M01AA06, kebuzone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Kebuzone.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Haloperidol.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Haloperidol.]
[A02BC05, esomeprazole, The serum concentration of Haloperidol can be increased when it is combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Haloperidol.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Haloperidol.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Haloperidol.]
[S01BA03, cortisone, The metabolism of Haloperidol can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Haloperidol can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Haloperidol.]
[M01AB09, lonazolac, The therapeutic efficacy of Haloperidol can be increased when used in combination with Lonazolac.]
[R06AX13, loratadine, The serum concentration of Haloperidol can be increased when it is combined with Loratadine.]
[N05CD06, lormetazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lormetazepam.]
[M02AA31, loxoprofen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C09AA03, lisinopril, Haloperidol may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Haloperidol may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The serum concentration of Haloperidol can be increased when it is combined with Manidipine.]
[A03AA04, mebeverine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Medifoxamine.]
[S01BA08, medrysone, The serum concentration of Haloperidol can be increased when it is combined with Medrysone.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Haloperidol.]
[H02AB15, meprednisone, The serum concentration of Haloperidol can be increased when it is combined with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Haloperidol.]
[J01DH02, meropenem, Haloperidol may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Haloperidol.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Haloperidol.]
[C04AX01, cyclandelate, The serum concentration of Haloperidol can be increased when it is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Methoxyphenamine can be decreased when used in combination with Haloperidol.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Haloperidol.]
[N05CA10, cyclobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cyclobarbital.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Haloperidol.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Haloperidol.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01FA03, midecamycin, The serum concentration of Haloperidol can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Haloperidol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.]
[N06AX07, minaprine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Minaprine.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Haloperidol.]
[S01XA18, cyclosporine, The serum concentration of Haloperidol can be increased when it is combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Haloperidol can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Haloperidol.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Haloperidol.]
[C10AA07, rosuvastatin, The serum concentration of Haloperidol can be increased when it is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Haloperidol can be increased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The serum concentration of Haloperidol can be increased when it is combined with Conivaptan.]
[J05AF10, entecavir, The metabolism of Haloperidol can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Haloperidol.]
[M01AH05, etoricoxib, The serum concentration of Haloperidol can be increased when it is combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Haloperidol.]
[G03XA01, danazol, The serum concentration of Haloperidol can be increased when it is combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dantrolene.]
[J04BA02, dapsone, The serum concentration of Haloperidol can be increased when it is combined with Dapsone.]
[L01DB02, daunorubicin, The serum concentration of Haloperidol can be increased when it is combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Deanol.]
[C02CC04, debrisoquin, The serum concentration of Debrisoquine can be increased when it is combined with Haloperidol.]
[G03XX01, prasterone, The serum concentration of Haloperidol can be increased when it is combined with Prasterone.]
[A04AD11, nabilone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nabilone.]
[M01AX01, nabumetone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Nabumetone.]
[N07BB05, nalmefene, Haloperidol may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nordazepam.]
[C07AB12, nebivolol, The serum concentration of Haloperidol can be increased when it is combined with Nebivolol.]
[S01GX04, nedocromil, Haloperidol may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Niaprazine.]
[C01DX16, nicorandil, Haloperidol may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, The metabolism of Haloperidol can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tiagabine.]
[G03DB04, nomegestrol, The serum concentration of Haloperidol can be increased when it is combined with Nomegestrol.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Haloperidol.]
[M03AC11, cisatracurium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Normethadone.]
[B01AX05, fondaparinux, Haloperidol may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[D11AH02, pimecrolimus, The serum concentration of Haloperidol can be increased when it is combined with Pimecrolimus.]
[N06AB10, escitalopram, The serum concentration of Haloperidol can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Haloperidol.]
[A07EC03, olsalazine, The therapeutic efficacy of Haloperidol can be increased when used in combination with Olsalazine.]
[N06AA01, desipramine, The serum concentration of Desipramine can be increased when it is combined with Haloperidol.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[S01BA11, desonide, The serum concentration of Haloperidol can be increased when it is combined with Desonide.]
[V04CH02, indigo carmine, Haloperidol may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C09XA02, aliskiren, The serum concentration of Haloperidol can be increased when it is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Haloperidol.]
[M01AE12, oxaprozin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Haloperidol can be increased when it is combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Haloperidol.]
[G04BD04, oxybutynin, The serum concentration of Haloperidol can be increased when it is combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The serum concentration of Dexfenfluramine can be increased when it is combined with Haloperidol.]
[A03AA01, oxyphencyclimine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Haloperidol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The serum concentration of Haloperidol can be increased when it is combined with Gefitinib.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.]
[R05DA09, dextromethorphan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of CNS depression can be increased when Haloperidol is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Paroxetine.]
[B01AC04, clopidogrel, The serum concentration of Haloperidol can be increased when it is combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Haloperidol.]
[A03AX15, peppermint oil, The serum concentration of Haloperidol can be increased when it is combined with Peppermint oil.]
[P03AC04, permethrin, Haloperidol may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phensuximide.]
[N06AA08, dibenzepin, The serum concentration of Dibenzepin can be increased when it is combined with Haloperidol.]
[S02DA04, dibucaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cinchocaine.]
[R05DA08, pholcodine, Haloperidol may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The serum concentration of Haloperidol can be increased when it is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Haloperidol.]
[A03AA07, dicyclomine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Haloperidol may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, The serum concentration of Haloperidol can be increased when it is combined with Pinacidil.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Haloperidol.]
[A10BG03, pioglitazone, The serum concentration of Haloperidol can be increased when it is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pipamperone.]
[A03AB14, pipenzolate, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The serum concentration of Haloperidol can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Erlotinib is combined with Haloperidol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The therapeutic efficacy of Diethylpropion can be decreased when used in combination with Haloperidol.]
[L02AA01, diethylstilbestrol, The serum concentration of Haloperidol can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Haloperidol.]
[D07XC04, diflucortolone, The serum concentration of Haloperidol can be increased when it is combined with Difluocortolone.]
[A03AB11, poldine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The therapeutic efficacy of Haloperidol can be increased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Haloperidol.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Haloperidol.]
[C02DB01, dihydralazine, The metabolism of Haloperidol can be decreased when combined with Dihydralazine.]
[C04AE04, dihydroergocristine, The serum concentration of Haloperidol can be increased when it is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Hydromorphone.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Haloperidol.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Haloperidol.]
[H03BC01, potassium perchlorate, Haloperidol may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Haloperidol may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pramocaine.]
[D07AC18, prednicarbate, The serum concentration of Haloperidol can be increased when it is combined with Prednicarbate.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Haloperidol.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Haloperidol.]
[V03AB09, dimercaprol, Haloperidol may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pridinol.]
[R06AB03, dimethindene, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The serum concentration of Haloperidol can be increased when it is combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Progabide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Haloperidol.]
[N02BB04, propyphenazone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Haloperidol can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Haloperidol.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Haloperidol.]
[A07DA01, diphenoxylate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The serum concentration of Quinupramine can be increased when it is combined with Haloperidol.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Cisapride is combined with Haloperidol.]
[S01XA23, sirolimus, The serum concentration of Haloperidol can be increased when it is combined with Sirolimus.]
[N05AL04, remoxipride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Remoxipride.]
[S01AX06, resorcinol, Haloperidol may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Haloperidol.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Haloperidol.]
[S02AA12, rifamycin SV, The serum concentration of Haloperidol can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The serum concentration of Haloperidol can be increased when it is combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of CNS depression can be increased when Haloperidol is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Haloperidol.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Haloperidol.]
[N01BB09, ropivacaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Haloperidol.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Haloperidol.]
[A04AD12, aprepitant, The serum concentration of Haloperidol can be increased when it is combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Haloperidol can be increased when it is combined with Tolvaptan.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Haloperidol.]
[J05AE07, fosamprenavir, The serum concentration of Haloperidol can be increased when it is combined with Fosamprenavir.]
[G04BE08, tadalafil, The serum concentration of Haloperidol can be increased when it is combined with Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, The serum concentration of Haloperidol can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be decreased when combined with Haloperidol.]
[N02BA06, salsalate, The therapeutic efficacy of Haloperidol can be increased when used in combination with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Haloperidol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C01CA07, dobutamine, Haloperidol may decrease the excretion rate of Dobutamine which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Domperidone is combined with Haloperidol.]
[C01CA04, dopamine, Haloperidol may decrease the excretion rate of Dopamine which could result in a higher serum level.]
[N06AA16, dothiepin, The serum concentration of Dosulepin can be increased when it is combined with Haloperidol.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Haloperidol.]
[L01DB01, doxorubicin, The serum concentration of Haloperidol can be increased when it is combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.]
[N06AB06, sertraline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Haloperidol.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Haloperidol.]
[A08AA10, sibutramine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sibutramine.]
[C10AA01, simvastatin, The serum concentration of Haloperidol can be increased when it is combined with Simvastatin.]
[A12CA02, sodium sulfate, Haloperidol may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[G03DB01, dydrogesterone, The serum concentration of Haloperidol can be increased when it is combined with Dydrogesterone.]
[R03DA01, dyphylline, Haloperidol may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[D01AC09, sulconazole, The serum concentration of Haloperidol can be increased when it is combined with Sulconazole.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Haloperidol.]
[N02CC01, sumatriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sumatriptan.]
[G01AF05, econazole, The serum concentration of Haloperidol can be increased when it is combined with Econazole.]
[V04CX07, edrophonium, Haloperidol may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Haloperidol.]
[H01AA01, corticotropin, The serum concentration of Haloperidol can be increased when it is combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Haloperidol.]
[L01AX03, temozolomide, Haloperidol may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The therapeutic efficacy of Haloperidol can be increased when used in combination with Tenoxicam.]
[D01BA02, terbinafine, The serum concentration of Haloperidol can be increased when it is combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Terodiline is combined with Haloperidol.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Haloperidol.]
[M03BX07, tetrazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of CNS depression can be increased when Haloperidol is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Emepronium.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Haloperidol.]
[G01AF08, tioconazole, The serum concentration of Haloperidol can be increased when it is combined with Tioconazole.]
[N05BA23, tofisopam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The serum concentration of Haloperidol can be increased when it is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Haloperidol.]
[N03AX11, topiramate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Haloperidol.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD11, triazulenone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of CNS depression can be increased when Haloperidol is combined with Triclofos.]
[A03AB08, tridihexethyl, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Haloperidol.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Haloperidol.]
[N01AB04, enflurane, The risk or severity of CNS depression can be increased when Haloperidol is combined with Enflurane.]
[C02CA06, urapidil, The risk or severity of CNS depression can be increased when Haloperidol is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Haloperidol.]
[N05AL06, veralipride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Veralipride.]
[L01CA04, vinorelbine, The serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Haloperidol.]
[N06AX16, venlafaxine, The serum concentration of Haloperidol can be increased when it is combined with Venlafaxine.]
[C08CA12, mepirodipine, The serum concentration of Haloperidol can be increased when it is combined with Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Haloperidol can be increased when it is combined with Epinephrine.]
[N05CF02, zolpidem, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The serum concentration of Haloperidol can be increased when it is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Haloperidol.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Haloperidol.]
[N05CF01, zopiclone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Haloperidol.]
[G02AB03, ergonovine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol.]
[L03AX05, pidotimod, Haloperidol may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Haloperidol.]
[N05CD04, estazolam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Estazolam.]
[A02BC02, pantoprazole, The serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.]
[H05BX01, cinacalcet, The serum concentration of Haloperidol can be increased when it is combined with Cinacalcet.]
[G03CA03, estradiol, The serum concentration of Haloperidol can be increased when it is combined with Estradiol.]
[L01XX11, estramustine, The serum concentration of Haloperidol can be increased when it is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Haloperidol can be increased when it is combined with Conjugated estrogens.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[R03BA05, fluticasone, The serum concentration of Haloperidol can be increased when it is combined with Fluticasone.]
[C10AA04, fluvastatin, The serum concentration of Haloperidol can be increased when it is combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C01CA15, gepefrine, The therapeutic efficacy of Gepefrine can be decreased when used in combination with Haloperidol.]
[N05CM08, ethchlorvynol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ethchlorvynol.]
[L02AA03, ethinyl estradiol, The serum concentration of Haloperidol can be increased when it is combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Haloperidol.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Haloperidol.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Haloperidol.]
[N03AB01, ethotoin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ethyl chloride.]
[M01AC06, meloxicam, The serum concentration of Haloperidol can be increased when it is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ethylmorphine.]
[N01AX07, etomidate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Etomidate.]
[L01CB01, etoposide, The serum concentration of Haloperidol can be increased when it is combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of QTc prolongation can be increased when Sertindole is combined with Haloperidol.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Haloperidol.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Haloperidol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Haloperidol.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Astemizole is combined with Haloperidol.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Terfenadine is combined with Haloperidol.]
[P01AX07, trimetrexate, Haloperidol may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Haloperidol.]
[N06AB08, fluvoxamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Haloperidol.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Haloperidol.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Haloperidol.]
[M01CB01, gold sodium thiomalate, Haloperidol may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[A05AA01, chenodeoxycholic acid, The serum concentration of Haloperidol can be increased when it is combined with Chenodeoxycholic acid.]
[B05AA05, dextran, Haloperidol may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Haloperidol.]
[A16AA01, levocarnitine, Haloperidol may decrease the excretion rate of Levocarnitine which could result in a higher serum level.]
[P02CA03, albendazole, The serum concentration of Haloperidol can be increased when it is combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Haloperidol.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Haloperidol.]
[N03AX26, fenfluramine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Fenfluramine.]
[M01AE04, fenoprofen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Fenoprofen.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Haloperidol.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Haloperidol.]
[L01BB06, clofarabine, Haloperidol may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, The serum concentration of Haloperidol can be increased when it is combined with Cevimeline.]
[G04BD02, flavoxate, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Haloperidol.]
[N02BG04, floctafenine, The therapeutic efficacy of Haloperidol can be increased when used in combination with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Haloperidol.]
[J02AX01, flucytosine, Haloperidol may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The serum concentration of Haloperidol can be increased when it is combined with Fludrocortisone.]
[V03AB25, flumazenil, Haloperidol may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The serum concentration of Haloperidol can be increased when it is combined with Flumethasone.]
[N07CA03, flunarizine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The serum concentration of Haloperidol can be increased when it is combined with Fluocinonide.]
[N06AA14, melitracen, The serum concentration of Melitracen can be increased when it is combined with Haloperidol.]
[H02AB03, fluocortolone, The serum concentration of Haloperidol can be increased when it is combined with Fluocortolone.]
[V03AZ01, ethanol, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Haloperidol can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The serum concentration of Haloperidol can be increased when it is combined with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Haloperidol.]
[N06AB03, fluoxetine, The metabolism of Haloperidol can be decreased when combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Fluphenazine.]
[D07AC07, flurandrenolide, The serum concentration of Haloperidol can be increased when it is combined with Flurandrenolide.]
[N05CD01, flurazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Flurazepam.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Haloperidol.]
[L02BB01, flutamide, The serum concentration of Haloperidol can be increased when it is combined with Flutamide.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[S02AA17, fosfomycin, Haloperidol may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Haloperidol.]
[M03AA01, alcuronium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Furazolidone.]
[J05AE10, darunavir, The serum concentration of Haloperidol can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Eszopiclone.]
[N05AL05, amisulpride, Haloperidol may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Haloperidol.]
[M03AC02, gallamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Haloperidol.]
[S01AD09, ganciclovir, Haloperidol may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of CNS depression can be increased when Haloperidol is combined with Bifemelane.]
[C10AB04, gemfibrozil, The serum concentration of Haloperidol can be increased when it is combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Haloperidol.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Haloperidol.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Haloperidol.]
[N04BC06, cabergoline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Cabergoline.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Haloperidol.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Haloperidol.]
[J05AG04, etravirine, The serum concentration of Haloperidol can be increased when it is combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Haloperidol.]
[G03XA02, gestrinone, The serum concentration of Haloperidol can be increased when it is combined with Gestrinone.]
[N01AH02, alfentanil, The risk or severity of CNS depression can be increased when Haloperidol is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Haloperidol.]
[A10BB01, glyburide, The serum concentration of Haloperidol can be increased when it is combined with Glyburide.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Haloperidol.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Haloperidol.]
[N05CM18, dexmedetomidine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Glutethimide.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Haloperidol.]
[C02CA04, doxazosin, The serum concentration of Haloperidol can be increased when it is combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Haloperidol.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Haloperidol.]
[M01CB04, aurothioglucose, Haloperidol may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Haloperidol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Haloperidol.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[S01EX01, guanethidine, Haloperidol may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Haloperidol.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Haloperidol.]
[D07AD02, halcinonide, The serum concentration of Haloperidol can be increased when it is combined with Halcinonide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Haloperidol.]
[N07XX04, sodium oxybate, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Haloperidol can be increased when used in combination with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Haloperidol may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The serum concentration of Haloperidol can be increased when it is combined with Fluticasone furoate.]
[N01AB01, halothane, The risk or severity of CNS depression can be increased when Haloperidol is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Haloperidol.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Haloperidol.]
[N06BX13, idebenone, Haloperidol may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Haloperidol.]
[N02CX03, iprazochrome, The risk or severity of CNS depression can be increased when Haloperidol is combined with Iprazochrome.]
[L01CE02, irinotecan, The serum concentration of Haloperidol can be increased when it is combined with Irinotecan.]
[N05CA21, allobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Haloperidol.]
[G03DC01, allylestrenol, The serum concentration of Haloperidol can be increased when it is combined with Allylestrenol.]
[A07EC02, mesalamine, The therapeutic efficacy of Haloperidol can be increased when used in combination with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Hexobarbital.]
[J05AG01, nevirapine, The serum concentration of Haloperidol can be increased when it is combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Haloperidol.]
[M02AA26, nimesulide, The serum concentration of Haloperidol can be increased when it is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Haloperidol.]
[C09AA04, perindopril, Haloperidol may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, The serum concentration of Haloperidol can be increased when it is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Haloperidol.]
[R05DA03, hydrocodone, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The serum concentration of Haloperidol can be increased when it is combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Haloperidol may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[G04BD06, propiverine, The serum concentration of Haloperidol can be increased when it is combined with Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Haloperidol.]
[N05AX07, prothipendyl, The risk or severity of CNS depression can be increased when Haloperidol is combined with Prothipendyl.]
[B05AA07, hetastarch, Haloperidol may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[G03DA03, 17-alpha-hydroxyprogesterone, The serum concentration of Haloperidol can be increased when it is combined with Hydroxyprogesterone.]
[L01XX05, hydroxyurea, The serum concentration of Haloperidol can be increased when it is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Hydroxyzine.]
[J04AB04, rifabutin, The serum concentration of Haloperidol can be increased when it is combined with Rifabutin.]
[S01BA13, rimexolone, The serum concentration of Haloperidol can be increased when it is combined with Rimexolone.]
[R02AX02, ibuprofen, The serum concentration of Haloperidol can be increased when it is combined with Ibuprofen.]
[B05XA08, sodium acetate, Haloperidol may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, Haloperidol may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, The serum concentration of Idarubicin can be increased when it is combined with Haloperidol.]
[L01AA06, ifosfamide, The serum concentration of Haloperidol can be increased when it is combined with Ifosfamide.]
[H01AC02, somatrem, The metabolism of Haloperidol can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of CNS depression can be increased when Haloperidol is combined with Sufentanil.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Haloperidol.]
[L01CD01, paclitaxel, The serum concentration of Haloperidol can be increased when it is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Haloperidol.]
[R01AD07, tixocortol, Haloperidol may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Haloperidol.]
[L01CE01, topotecan, The serum concentration of Haloperidol can be increased when it is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Haloperidol.]
[S01BC01, indomethacin, The therapeutic efficacy of Haloperidol can be increased when used in combination with Indomethacin.]
[A11HA07, inositol, Haloperidol may decrease the excretion rate of Inositol which could result in a higher serum level.]
[L03AB04, interferon alfa-2a, The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Haloperidol can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of CNS depression can be increased when Haloperidol is combined with Milnacipran.]
[A03AA30, piperidolate, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Haloperidol may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Articaine.]
[A10BH01, sitagliptin, The serum concentration of Haloperidol can be increased when it is combined with Sitagliptin.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Haloperidol.]
[N05CH02, ramelteon, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Haloperidol.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Haloperidol.]
[C10AA06, cerivastatin, The serum concentration of Haloperidol can be increased when it is combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Haloperidol.]
[C07AA01, alprenolol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB09, interferon alfacon-1, The metabolism of Haloperidol can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The serum concentration of Haloperidol can be increased when it is combined with Ipecac.]
[J05AF04, stavudine, Haloperidol may increase the neurotoxic activities of Stavudine.]
[N06AA13, iprindole, The serum concentration of Iprindole can be increased when it is combined with Haloperidol.]
[N06AF05, iproniazid, The risk or severity of CNS depression can be increased when Haloperidol is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Haloperidol can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Chlorproethazine.]
[D06BB10, imiquimod, The serum concentration of Haloperidol can be increased when it is combined with Imiquimod.]
[N06AF01, isocarboxazid, The risk or severity of CNS depression can be increased when Haloperidol is combined with Isocarboxazid.]
[P01AX06, atovaquone, The serum concentration of Haloperidol can be increased when it is combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Haloperidol.]
[N04BX02, entacapone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Entacapone.]
[J04AC01, isoniazid, The serum concentration of Haloperidol can be increased when it is combined with Isoniazid.]
[J05AX05, inosine pranobex, Haloperidol may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Haloperidol.]
[D10BA01, isotretinoin, The serum concentration of Haloperidol can be increased when it is combined with Isotretinoin.]
[P02CF01, ivermectin, The serum concentration of Haloperidol can be increased when it is combined with Ivermectin.]
[N06AX18, reboxetine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Reboxetine.]
[S01AA24, kanamycin, Haloperidol may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[H01AC01, somatropin, The metabolism of Haloperidol can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Haloperidol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ketanserin.]
[B01AC22, prasugrel, The serum concentration of Haloperidol can be increased when it is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Haloperidol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Haloperidol.]
[M02AA10, ketoprofen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Haloperidol can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Haloperidol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Haloperidol.]
[N04BC09, rotigotine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Haloperidol.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Haloperidol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Haloperidol.]
[J05AX09, maraviroc, The serum concentration of Haloperidol can be increased when it is combined with Maraviroc.]
[A06AX03, lubiprostone, Haloperidol may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lacosamide.]
[R05CB06, ambroxol, The serum concentration of Haloperidol can be increased when it is combined with Ambroxol.]
[G03AD01, levonorgestrel, The serum concentration of Haloperidol can be increased when it is combined with Levonorgestrel.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Haloperidol.]
[S02DA01, lidocaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Haloperidol.]
[J01FF02, lincomycin, Haloperidol may increase the neurotoxic activities of Lincomycin.]
[S01AA21, amikacin, Haloperidol may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[N06BA13, armodafinil, The metabolism of Haloperidol can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Haloperidol.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lisuride.]
[N06AA07, lofepramine, The serum concentration of Lofepramine can be increased when it is combined with Haloperidol.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Haloperidol.]
[N05BA06, lorazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lorazepam.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Haloperidol.]
[N05AH01, loxapine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Loxapine.]
[G03DC03, lynestrenol, The serum concentration of Haloperidol can be increased when it is combined with Lynestrenol.]
[L01EG01, temsirolimus, The serum concentration of Haloperidol can be increased when it is combined with Temsirolimus.]
[B05XA11, magnesium chloride, Haloperidol may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Haloperidol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Haloperidol can be increased when used in combination with Magnesium sulfate.]
[P03AX03, malathion, The risk or severity of QTc prolongation can be increased when Malathion is combined with Haloperidol.]
[L01BA05, pralatrexate, Haloperidol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Nilotinib is combined with Haloperidol.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Haloperidol.]
[A08AA05, mazindol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Mazindol.]
[C02BB01, mecamylamine, Haloperidol may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[R06AE05, meclizine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Meclizine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Haloperidol can be increased when used in combination with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Medazepam.]
[G03DB03, medrogestone, The serum concentration of Haloperidol can be increased when it is combined with Medrogestone.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Haloperidol.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Melatonin.]
[N06DX01, memantine, The risk or severity of adverse effects can be increased when Haloperidol is combined with Memantine.]
[N02AB02, meperidine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Meperidine.]
[M03BX06, mephenesin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Mephenesin.]
[C01CA11, mephentermine, The therapeutic efficacy of Mephentermine can be decreased when used in combination with Haloperidol.]
[N03AB04, mephenytoin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Mephenytoin.]
[N03AA01, mephobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Meptazinol.]
[G04BX16, tiopronin, Haloperidol may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Haloperidol.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Paliperidone is combined with Haloperidol.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Haloperidol.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Haloperidol.]
[H01CB03, lanreotide, The serum concentration of Haloperidol can be increased when it is combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.]
[N06BA03, methamphetamine, The therapeutic efficacy of Metamfetamine can be decreased when used in combination with Haloperidol.]
[A03AB07, methantheline, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methaqualone.]
[J05AF05, lamivudine, Haloperidol may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Metharbital.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Metergoline.]
[H03BB02, methimazole, The serum concentration of Haloperidol can be increased when it is combined with Methimazole.]
[L01BA04, pemetrexed, Haloperidol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methohexital.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Ziconotide.]
[L04AX03, methotrexate, The serum concentration of Haloperidol can be increased when it is combined with Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Haloperidol.]
[D05BA02, methoxsalen, The metabolism of Haloperidol can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Haloperidol may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methylene blue.]
[G02AB01, methylergonovine, The serum concentration of Haloperidol can be increased when it is combined with Methylergometrine.]
[R03DA05, aminophylline, The serum concentration of Haloperidol can be increased when it is combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The serum concentration of Haloperidol can be increased when it is combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Rufinamide.]
[G03EK01, methyltestosterone, The serum concentration of Haloperidol can be increased when it is combined with Methyltestosterone.]
[N05CE02, methyprylon, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The serum concentration of Metoprolol can be increased when it is combined with Haloperidol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Haloperidol.]
[V04CD01, metyrapone, The serum concentration of Haloperidol can be increased when it is combined with Metyrapone.]
[C01BB02, mexiletine, The serum concentration of Haloperidol can be increased when it is combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Mianserin.]
[S02AA13, miconazole, The serum concentration of Haloperidol can be increased when it is combined with Miconazole.]
[N02BB03, aminopyrine, The serum concentration of Haloperidol can be increased when it is combined with Aminophenazone.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Haloperidol.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Mifepristone is combined with Haloperidol.]
[J05AH01, zanamivir, Haloperidol may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The metabolism of Haloperidol can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.]
[L01XX23, mitotane, The metabolism of Haloperidol can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Lisdexamfetamine can be decreased when used in combination with Haloperidol.]
[N05AE02, molindone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Molindone.]
[L03AC01, aldesleukin, The serum concentration of Haloperidol can be increased when it is combined with Aldesleukin.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Haloperidol.]
[N06AA09, amitriptyline, The serum concentration of Amitriptyline can be increased when it is combined with Haloperidol.]
[N02AA01, morphine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of CNS depression can be increased when Haloperidol is combined with Palonosetron.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Haloperidol can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Haloperidol.]
[G04BA01, ammonium chloride, Haloperidol may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Haloperidol.]
[L04AA06, mycophenolic acid, Haloperidol may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Haloperidol.]
[G04CA04, silodosin, The serum concentration of Haloperidol can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The serum concentration of Haloperidol can be increased when it is combined with Raloxifene.]
[N06AA17, amoxapine, The serum concentration of Amoxapine can be increased when it is combined with Haloperidol.]
[N03AB05, fosphenytoin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Haloperidol can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Haloperidol.]
[J01CA04, amoxicillin, Haloperidol may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Haloperidol.]
[J01CF06, nafcillin, The metabolism of Haloperidol can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of CNS depression can be increased when Haloperidol is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nalbuphine.]
[V03AB15, naloxone, The serum concentration of Haloperidol can be increased when it is combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Haloperidol can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The therapeutic efficacy of Amphetamine can be decreased when used in combination with Haloperidol.]
[M02AA12, naproxen, The therapeutic efficacy of Haloperidol can be increased when used in combination with Naproxen.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Haloperidol.]
[N06AX21, duloxetine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Tolcapone.]
[L01CD02, docetaxel, The serum concentration of Haloperidol can be increased when it is combined with Docetaxel.]
[L02BG04, letrozole, The serum concentration of Haloperidol can be increased when it is combined with Letrozole.]
[S03AA01, neomycin, Haloperidol may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of CNS depression can be increased when Haloperidol is combined with Remifentanil.]
[A10BX02, repaglinide, The serum concentration of Haloperidol can be increased when it is combined with Repaglinide.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Haloperidol.]
[B01AC17, tirofiban, Haloperidol may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Haloperidol.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[L03AX16, plerixafor, Haloperidol may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Haloperidol may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Desvenlafaxine.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[H05BX02, paricalcitol, The serum concentration of Haloperidol can be increased when it is combined with Paricalcitol.]
[C01CE01, inamrinone, Haloperidol may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The serum concentration of Haloperidol can be increased when it is combined with Niacin.]
[N06AF02, nialamide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Haloperidol.]
[C04AE02, nicergoline, The serum concentration of Nicergoline can be increased when it is combined with Haloperidol.]
[P02DA01, niclosamide, The metabolism of Haloperidol can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Haloperidol.]
[M02AA17, niflumic acid, The therapeutic efficacy of Haloperidol can be increased when used in combination with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Haloperidol.]
[C08CA07, nisoldipine, The serum concentration of Haloperidol can be increased when it is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Haloperidol.]
[R07AX01, nitric oxide, The serum concentration of Haloperidol can be increased when it is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, Haloperidol may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of CNS depression can be increased when Haloperidol is combined with Zaleplon.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Haloperidol.]
[C02DD01, nitroprusside, Nitroprusside may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N01AX13, nitrous oxide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Nomifensine.]
[G03DC02, norethindrone, The serum concentration of Haloperidol can be increased when it is combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Haloperidol.]
[C02KX01, bosentan, The serum concentration of Haloperidol can be increased when it is combined with Bosentan.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Haloperidol.]
[R05DA07, noscapine, The serum concentration of Haloperidol can be increased when it is combined with Noscapine.]
[L03AB07, interferon beta-1a, The metabolism of Haloperidol can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The serum concentration of Haloperidol can be increased when it is combined with Nylidrin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Haloperidol.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Haloperidol.]
[J01FA05, oleandomycin, The serum concentration of Haloperidol can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Haloperidol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The serum concentration of Haloperidol can be increased when it is combined with Omeprazole.]
[N06AA05, opipramol, The serum concentration of Opipramol can be increased when it is combined with Haloperidol.]
[N02AA02, opium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Opium.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.]
[G04CA02, tamsulosin, The serum concentration of Haloperidol can be increased when it is combined with Tamsulosin.]
[J01CF04, oxacillin, Haloperidol may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[P02BA02, oxamniquine, The serum concentration of Haloperidol can be increased when it is combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Haloperidol can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Haloperidol.]
[C07AA02, oxprenolol, The risk or severity of QTc prolongation can be increased when Oxprenolol is combined with Haloperidol.]
[N02AA05, oxycodone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxycodone.]
[A14AA05, oxymetholone, The serum concentration of Haloperidol can be increased when it is combined with Oxymetholone.]
[N02AA11, oxymorphone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Haloperidol.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Asenapine is combined with Haloperidol.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.]
[M03AC01, pancuronium, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pancuronium.]
[J04AB30, capreomycin, Haloperidol may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G03DB06, chlormadinone, The serum concentration of Haloperidol can be increased when it is combined with Chlormadinone.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Haloperidol.]
[N05CC05, paraldehyde, The risk or severity of CNS depression can be increased when Haloperidol is combined with Paraldehyde.]
[H02AB05, paramethasone, The serum concentration of Haloperidol can be increased when it is combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Haloperidol.]
[G04BD11, fesoterodine, The serum concentration of Haloperidol can be increased when it is combined with Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Haloperidol.]
[J01CE09, penicillin G procaine, Haloperidol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pentobarbital.]
[L01XX08, pentostatin, Haloperidol may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Haloperidol.]
[N05AB10, perazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Haloperidol.]
[N05AB03, perphenazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Perphenazine.]
[N02BE03, phenacetin, The serum concentration of Haloperidol can be increased when it is combined with Phenacetin.]
[N02AD02, phenazocine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N06AF03, phenelzine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenelzine.]
[A10BA01, phenformin, The serum concentration of Phenformin can be increased when it is combined with Haloperidol.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Haloperidol.]
[N03AA02, phenobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The serum concentration of Haloperidol can be increased when it is combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Phentermine can be decreased when used in combination with Haloperidol.]
[V03AB36, phentolamine, Haloperidol may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Haloperidol can be increased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Haloperidol can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The serum concentration of Haloperidol can be increased when it is combined with Dexlansoprazole.]
[N03AB02, phenytoin, The risk or severity of CNS depression can be increased when Haloperidol is combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Haloperidol can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Haloperidol.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Haloperidol.]
[L02BB03, bicalutamide, The serum concentration of Haloperidol can be increased when it is combined with Bicalutamide.]
[B02BA01, vitamin K1, Haloperidol may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Haloperidol.]
[S01EB01, pilocarpine, The serum concentration of Haloperidol can be increased when it is combined with Pilocarpine.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Pimozide is combined with Haloperidol.]
[C07AA03, pindolol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Haloperidol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Haloperidol.]
[P02CB01, piperazine, The serum concentration of Piperazine can be increased when it is combined with Haloperidol.]
[N05AC04, pipothiazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pipotiazine.]
[N06BX03, piracetam, Haloperidol may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[A02BX03, pirenzepine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Haloperidol.]
[N02AC03, pirinitramide, The risk or severity of CNS depression can be increased when Haloperidol is combined with Piritramide.]
[S01BC06, piroxicam, The therapeutic efficacy of Haloperidol can be increased when used in combination with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Haloperidol.]
[N02CX01, pizotyline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pizotifen.]
[J05AG02, delavirdine, The serum concentration of Haloperidol can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The serum concentration of Haloperidol can be increased when it is combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of CNS depression can be increased when Haloperidol is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The serum concentration of Haloperidol can be increased when it is combined with Rosiglitazone.]
[A03AE01, alosetron, The risk or severity of CNS depression can be increased when Haloperidol is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Haloperidol can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Haloperidol may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The serum concentration of Haloperidol can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The serum concentration of Haloperidol can be increased when it is combined with Saxagliptin.]
[B05XA01, potassium chloride, Haloperidol may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Haloperidol.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Haloperidol.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Haloperidol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Haloperidol.]
[N05BA11, prazepam, The risk or severity of CNS depression can be increased when Haloperidol is combined with Prazepam.]
[P02BA01, praziquantel, The serum concentration of Haloperidol can be increased when it is combined with Praziquantel.]
[S03BA02, prednisolone, The serum concentration of Haloperidol can be increased when it is combined with Prednisolone.]
[H02AB07, prednisone, The serum concentration of Haloperidol can be increased when it is combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Haloperidol.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Haloperidol.]
[N01BB04, prilocaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Haloperidol.]
[N03AA03, primidone, The risk or severity of CNS depression can be increased when Haloperidol is combined with Primidone.]
[M04AB01, probenecid, The metabolism of Haloperidol can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Haloperidol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Procainamide is combined with Haloperidol.]
[S01HA05, procaine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Procarbazine.]
[C10AB05, fenofibrate, The serum concentration of Haloperidol can be increased when it is combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Haloperidol.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Haloperidol.]
[G03DA04, progesterone, The serum concentration of Haloperidol can be increased when it is combined with Progesterone.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Haloperidol.]
[G03DB07, promegestone, The serum concentration of Haloperidol can be increased when it is combined with Promegestone.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Haloperidol.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Haloperidol.]
[N01AX04, propanidid, The risk or severity of CNS depression can be increased when Haloperidol is combined with Propanidid.]
[A03AB05, propantheline, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Romidepsin is combined with Haloperidol.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Haloperidol.]
[N02AC04, propoxyphene, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The risk or severity of QTc prolongation can be increased when Propranolol is combined with Haloperidol.]
[N02CC04, rizatriptan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Rizatriptan.]
[B01AC09, epoprostenol, Haloperidol may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[R03DC03, montelukast, The serum concentration of Haloperidol can be increased when it is combined with Montelukast.]
[N06AA11, protriptyline, The serum concentration of Protriptyline can be increased when it is combined with Haloperidol.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Haloperidol.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Haloperidol.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Haloperidol is combined with Dalfampridine.]
[S01EB03, ecothiopate, The risk or severity of QTc prolongation can be increased when Echothiophate is combined with Haloperidol.]
[A03AB15, diphemanil, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of CNS depression can be increased when Haloperidol is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of CNS depression can be increased when Haloperidol is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Haloperidol.]
[P01AX05, quinacrine, The serum concentration of Haloperidol can be increased when it is combined with Quinacrine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Quinidine is combined with Haloperidol.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Quinine is combined with Haloperidol.]
[A02BA02, ranitidine, The serum concentration of Haloperidol can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Reserpine.]
[J05AP01, ribavirin, Haloperidol may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Haloperidol can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of CNS depression can be increased when Haloperidol is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Haloperidol.]
[C05CA01, rutin, The serum concentration of Haloperidol can be increased when it is combined with Rutin.]
[N02BA05, salicylamide, The therapeutic efficacy of Haloperidol can be increased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Haloperidol can be increased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Haloperidol can be increased when used in combination with Salicylic acid.]
[S01FA02, scopolamine, The risk or severity of CNS depression can be increased when Haloperidol is combined with Scopolamine.]
[N05CA06, secobarbital, The risk or severity of CNS depression can be increased when Haloperidol is combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of CNS depression can be increased when Haloperidol is combined with Selegiline.]
[J01GB08, sisomicin, Haloperidol may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Haloperidol may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[H01CB01, somatostatin, The serum concentration of Haloperidol can be increased when it is combined with Somatostatin.]
[V04CC01, sorbitol, Haloperidol may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Haloperidol.]
[L01CD04, cabazitaxel, The serum concentration of Haloperidol can be increased when it is combined with Cabazitaxel.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC16, hydrocortisone aceponate, The serum concentration of Haloperidol can be increased when it is combined with Hydrocortisone aceponate.]
[D07AB02, hydrocortisone butyrate, The serum concentration of Haloperidol can be increased when it is combined with Hydrocortisone butyrate.]
[D07AB11, hydrocortisone probutate, The serum concentration of Haloperidol can be increased when it is combined with Hydrocortisone probutate.]
[C01DA14, isosorbide mononitrate, Haloperidol may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[H02CA04, levoketoconazole, The risk or severity of QTc prolongation can be increased when Levoketoconazole is combined with Haloperidol.]
[D10AX03, azelaic acid, Haloperidol may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Haloperidol can be increased when used in combination with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Haloperidol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BB01, ipratropium bromide, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
